Production (Stage)
E
Artiva Biotherapeutics, Inc. ARTV
$1.95 -$0.03-1.52% NASDAQ
Recommendation
Prev Close
$1.95
Volume
74,241
Avg Vol (90D)
247,363
Market Cap
$47.51M
Dividend & Yield
--
52-Week Range
$1.78 - $17.31
P/E (TTM)
--
EPS (TTM)
-$25.08
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Needham & Company LLC Lowers Artiva Biotherapeutics (NASDAQ:ARTV) Price Target to $18.00
5/15/2025 - Ticker Report
Needham Remains a Buy on Artiva Biotherapeutics, Inc. (ARTV)
5/14/2025 - TipRanks Financial Blog
Artiva Biotherapeutics announces new, long-term data for AlloNK combination
5/13/2025 - TipRanks Financial Blog
Artiva Biotherapeutics announces new, long-term data for AlloNK combination
5/13/2025 - The Fly
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
5/13/2025 - Globe Newswire
Q1 Earnings Estimate for ARTV Issued By Wedbush
5/13/2025 - MarketBeat
Artiva Biotherapeutics (NASDAQ:ARTV) Releases Quarterly Earnings Results, Misses Expectations By $0.15 EPS
5/12/2025 - MarketBeat
Artiva Biotherapeutics Reports Q1 2025 Progress
5/11/2025 - TipRanks Financial Blog
Artiva Biotherapeutics Inc Reports Q1 2025 Net Loss of $20. ...
5/10/2025 - GuruFocus
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
5/8/2025 - GuruFocus
Artiva Biotherapeutics sees cash runway into 2Q27
5/8/2025 - The Fly
Artiva Biotherapeutics reports Q1 EPS (83c) vs. ($17.24) last year
5/8/2025 - The Fly
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
5/8/2025 - Globe Newswire
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Buy" by Brokerages
5/6/2025 - MarketBeat
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
4/28/2025 - Globe Newswire
Surprising Analyst 12-Month Target For IBBQ
4/16/2025 - ETF Channel
Artiva Biotherapeutics (NASDAQ:ARTV) Earns "Buy" Rating from Needham & Company LLC
4/10/2025 - MarketBeat
Artiva Biotherapeutics (ARTV) Leads Surge in Biotech Stock Interest ARTV Stock News
4/9/2025 - GuruFocus
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
4/8/2025 - GuruFocus
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer ARTV Stock News
4/8/2025 - GuruFocus
Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds
4/8/2025 - TipRanks Financial Blog
Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer
4/8/2025 - Globe Newswire
Artiva Biotherapeutics Reports 2024 Financial Results
4/2/2025 - TipRanks Financial Blog
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
3/31/2025 - GuruFocus
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
3/31/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
$0.00
EBITDA (TTM)
-$72.49M
EBIT (TTM)
-$74.96M
Net Income (TTM)
-$71.72M
Balance Sheet
Total Assets (Q)
$191.26M
Total Debt (Q)
$14.00M
Total Liabilities (Q)
$22.48M
Book Value Per Share (Q)
$6.93
Cash Flow
Cash from Operations (TTM)
-$59.79M
Cash from Investing (TTM)
-$120.27M
Cash from Financing (TTM)
$162.47M
Net Change in Cash (TTM)
-$17.60M
Filings
Filing Date
Thursday, May 8, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Jun 23 and 27 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-8.45%
30-Day Total Return
-1.52%
60-Day Total Return
-53.01%
90-Day Total Return
-72.61%
Year to Date Total Return
-80.44%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $1.78
52-week High
Oct 01, 2024 - $17.31
Valuation
Market Cap
$47.51M - Nano Cap
Enterprise Value
-$104.46M
Price/Sales (TTM)
--
Price/Book (Q)
0.28
Dividends and Shares
Shares Outstanding
24.34M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.artivabio.com
Phone Number
858 267 4467
Address
5505 Morehouse Drive
San Diego, CA 92121
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed